88611-67-0

Basic information

• Product Name: N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide
• Synonyms: 6-ACETAMIDO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-ONE;N1-(5-OXO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)ACETAMIDE;6-Acetamido-1,2,3,4-tetrahydronaphthalen-1-one 97%;6-ACETAMIDO-1,2,3,4-TETRAHYDRONAPHTHALENE-1-ONE;N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide;6-Acetamido-1,2,3,4-tetrahydronaphthalen-1-one97%;N-(5-Oxo-5,6,7,8-tetrahydrophthalen-2-yl)acetamide;N-(5-oxo-7,8-dihydro-6H-naphthalen-2-yl)acetamide
• CAS NO: 88611-67-0
• Molecular Formula: C₁₂H₁₃NO₂
• Molecular Weight: 203.24
• Product Categories: Fused Ring Systems
• Mol File: 88611-67-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 127 °C
• Boiling Point: 439.6 °C at 760 mmHg
• Flash Point: 193.5 °C
• Appearance: /
• Density: 1.225g/cm³
• Vapor Pressure: 6.27E-08mmHg at 25°C
• Refractive Index: 1.609
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.56±0.20(Predicted)
• CAS DataBase Reference: N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide(88611-67-0)
• EPA Substance Registry System: N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide(88611-67-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 24/25
• Hazardous Substances Data: 88611-67-0(Hazardous Substances Data)

Usage

General Description

N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide is a chemical compound with the molecular formula C14H15NO2. It is an amide derivative of 2-acetylnaphthalene, a derivative of naphthalene. N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide has potential biological activities and is often studied for its pharmaceutical properties. It is commonly used in research and drug development, particularly in the study of its effects on the central nervous system and as a potential treatment for various neurological disorders. N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide shows promise as a therapeutic agent and its chemical properties make it an important compound in the field of pharmacology.

InChI:InChI=1/C12H13NO2/c1-8(14)13-10-5-6-11-9(7-10)3-2-4-12(11)15/h5-7H,2-4H2,1H3,(H,13,14)

Upstream product

• 3470-53-9 6-amino-1-tetralone 
• 75-36-5 acetyl chloride 
• 6328-00-3 4-(3-nitro-phenyl)-4-oxo-butyric acid 
• 2051-95-8 succinylbenzene 
• 14714-31-9 β-<3-Acetylamino-benzoyl>-propionsaeure 
• 108-24-7 acetic anhydride 
• 50878-03-0 N-(5,6,7,8-tetrahydronaphth-2-yl)acetamide 

Downstream Products

• 3470-53-9 6-amino-1-tetralone 
• 66361-67-9 6-bromo-3,4-dihydro-2H-naphthalen-1-one 
• 125564-40-1 1-tetralone-6-acetic acid 
• 1000300-19-5 ((R)-6-chlorosulfonyl-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-carbamic acid benzyl ester 
• 1000300-17-3 ((R)-6-iodo-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-carbamic acid benzyl ester 
• 895534-29-9 (S)-6-iodo-1,2,3,4-tetrahydro-naphthalen-1-ol 
• 103796-57-2 6-amino-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid 
• 66361-80-6 6-(methylsulfonylamino)-1-tetralone 
• 138814-34-3 6-(acetylamino)-7-nitro-1-<<4-(phenylsulfonyl)phenyl>thio>-1,2,3,4-tetrahydronaphthalene 
• 138814-35-4 6-amino-7-nitro-1-<<4-(phenylsulfonyl)phenyl>thio>-1,2,3,4-tetrahydronaphthalene 
• 138834-44-3 2-amino-5-<<4-(phenylsulfonyl)phenyl>thio>-5,6,7,8-tetrahydronaphth<2,3-d>imidazole 
• 138814-36-5 6,7-diamino-1-<<4-(phenylsulfonyl)phenyl>thio>-1,2,3,4-tetrahydronaphthalene 
• 88285-36-3 N-[6-(4-Benzhydryl-piperazin-1-ylmethyl)-7,8-dihydro-naphthalen-2-yl]-butyramide 

Relevant articles and documents

Ratiometric fluorescence assay for nitroreductase activity: Locked-Flavylium fluorophore as a NTR-sensitive molecular probe

Nitroreductases belong to a member of flavin-containing enzymes that can reduce nitroaromatic compounds to amino derivatives with NADH as an electron donor. NTR activity is known to be elevated in the cancerous environment and is considered an advantageous target in therapeutic prodrugs for the treatment of cancer. Here, we developed a ratiometric fluorescent molecule for observing NTR activity in living cells. This can provide a selective and sensitive response to NTR with a distinct increase in fluorescence ratio (FI530/FI630) as well as color changes. We also found a significant increase in NTR activity in cervical cancer HeLa and lung cancer A549 cells compared to non-cancerous NIH3T3. We proposed that this new ratiometric fluorescent molecule could potentially be used as a NTR-sensitive molecular probe in the field of cancer diagnosis and treatment development related to NTR activity.

Discovery, synthesis, and structure-activity relationship of 6-aminomethyl-7,8-dihydronaphthalenes as human melanin-concentrating hormone receptor 1 antagonists

Human melanin-concentrating hormone receptor 1 (hMCHR1) antagonists are promising targets for obesity treatment. We identified the tetrahydronaphthalene derivative 1a with modest binding affinity for hMCHR1 by screening an in-house G protein-coupled receptor (GPCR) ligand library. We synthesized a series of 6-aminomethyl-5,6,7,8-tetrahydronaphthalenes and evaluated their activity as hMCHR1 antagonists. Modification of the biphenylcarbonylamino group revealed that the biphenyl moiety played a crucial role in the interaction of the antagonist with the receptor. The stereoselective effect of the chiral center on binding affinity generated the novel 6-aminomethyl-7,8-dihydronaphthalene scaffold without a chiral center. Optimization of the amino group led to the identification of a potent antagonist 2s (4′-fluoro-N-[6-(1- pyrrolidinylmethyl)-7,8-dihydro-2-naphthalenyl][1,1′-biphenyl] -4-carboxamide), which significantly inhibited the nocturnal food intake in rats after oral administration. Pharmacokinetic analysis confirmed that 2s had good oral bioavailability and brain penetrance. This antagonist appears to be a viable lead compound that can be used to develop a promising therapy for obesity.

ORGANIC COMPOUNDS

The present invention provides a compound of formula I: said compound is inhibitor of aldosterone synthase (CYP11B2), and/or 11beta-hydroxylase (CYP11B1), and/or aromatase, and thus can be employed for the treatment of a disorder or disease mediated by al